← Back to Retailer Search

The CVS Health NOligarchy Profile

A
V
O
I
D
NOligarchy Score
16.2
/ 100
cvs.com
0
CVS Health earns a NOligarchy Score of 16.23 out of 100, placing it in the lowest tier of corporate accountability tracked by this profile.
Current Pillar Scores
Political Access
7.8
Wealth Extraction
32.6
Playing by the Rules
6.5
Score history — 24 quarters
TRUSTEDMODERATECONCERNINGAVOIDNov '20 electionNov '22 electionNov '24 election30.016.2−5.1 · 1yrQ4 '20Q4 '21Q4 '22Q4 '23Q4 '24Q3 '26 · now
Tier bands show where each quarter's score falls — no numeric y-axis needed. The dashed ring marks the year-over-year comparison point. Tap any quarter but the first to see its pillar breakdown.
This score is built from three pillar grades covering from Q4 2024 through Q3 2026 (8 quarters — the two-year tracking period):
•
Political Access Grade: 7.79/100. CVS Health’s federal lobbying spend, Political Action Committee (PAC) contributions, and an army of revolving-door lobbyists collectively drag this grade to the floor.
•
Wealth Extraction Grade: 32.6/100. Reflects a CEO-to-median-worker pay gap of 503-to-1, a $3 billion buyback program in fiscal 2024, and continued dividend flows to investors across both tracked fiscal years.
•
Playing by the Rules Grade: 6.55/100. Driven by $357,762,787 in total fines across 35 cases — the second-highest penalty total in its sector.
The Sector Context: CVS Health ranks 5th out of 5 companies in the federal industry classification for Health and Personal Care Retailers — dead last. The sector average NOligarchy Score is 40.8; CVS Health’s 16.23 falls far below that baseline. For higher-scoring alternatives in this space, see the Better Alternatives section below.

The Bottom Line: A Company Fined Hundreds of Millions While Handing Billions to Shareholders

CVS Health pulled in $402,067,000,000 in global revenue (SEC EDGAR 10-K (CIK 0000064803)) — the kind of money that makes a $357,762,787 fine bill look manageable, even though it is the second-largest penalty total in its own sector. In the same stretch, the company spent $3,023,000,000 buying back its own stock and channeled roughly $6,770,000,000 in dividends to investors, while its CEO earned 503 times more than the company’s median worker. CVS Health’s combined political and influence spending topped $21.8 million — equivalent to 270 years of median-household income — while regulators kept collecting. The fines were paid; the buybacks happened; the pay gap remained wide. Nothing in the public record suggests these were forced choices — they were the choices CVS Health made with the money it had.
CVS Health's $21.8 million in political spending equals 270 years of median-household income — enough people, one per year worked, to fill 1.5 fully-boarded 737s.

Spending to Buy a Seat at the Table

CVS Health poured $20,660,000 into federal lobbying (Senate Lobbying Disclosure Act (LDA)) across the two-year period, on top of $952,000 deployed through its corporate PAC (Federal Election Commission (FEC)) and $174,099 in personal donations from its executives.
Lobbying spend climbed sharply after Q4 2024’s $2,040,000 entry, with $9,690,000 spent across all of 2025 before reaching $8,930,000 in just the first three quarters of 2026. CVS Health’s lobbyists filed 47 reports on health issues, 42 on pharmacy, 20 on Medicare and Medicaid, and 15 on insurance — a lineup that tracks directly to a company running a national pharmacy chain, a pharmacy benefit manager (PBM) operation through CVS Caremark, and the insurer Aetna. Filings cited the Ensuring Community Access to Pharmacist Services Act (H.R. 3164) — currently advancing through committee — seven times, and its Senate companion, the Equitable Community Access to Pharmacist Services Act (S. 2426), six times. These bills would expand pharmacists’ authority to provide clinical services, a matter of direct commercial interest to CVS’s retail pharmacy footprint. Lobbyists also cited the Patients Before Middlemen Act (S. 882) and the Protecting Pharmacies in Medicaid Act (S. 927) six times each — both targeting PBM practices squarely relevant to CVS Caremark. Under consumer issues filings, lobbyists referenced the Combating Organized Retail Crime Act of 2025 (H.R. 2853), which addresses theft at retail locations — cited five times and now received in the Senate. Tax filings cited the No Handouts for Drug Advertisements Act (H.R. 3010 and S. 1785), which would restrict deductions for prescription drug advertising costs, touching CVS’s interests both as a pharmacy and as an insurer. None of these bills had been enacted as of the latest filings; most remain in progress.
The PAC split its giving nearly evenly: $313,500 to Democrats and $322,500 to Republicans — a 49.3% / 50.7% division that buys access to whichever party controls the next Congress.
CVS Health's PAC gave $313,500 to Democrats and $322,500 to Republicans — a 49.3% / 50.7% split that buys access to whichever party wins.
49.3%
50.7%
Democrats · $313,500
Republicans · $322,500
ACCESS-BUYER PENALTY APPLIED
CVS Health’s 114 registered lobbyists include 81 with prior government positions. Among them: a former United States Senator (Thomas Daschle), a former Special Assistant to the President at the White House, a former Director of Strategic Communications at the Centers for Medicare & Medicaid Services (CMS), and a former Health Policy Director for Senator Chuck Grassley — giving the company direct lines into virtually every office it now lobbies. CVS Health also shares lobbying firms with competitors and other large corporations: BGR Government Affairs represents CVS and Walgreens Boots Alliance simultaneously, while Kountoupes Denham Carr & Reid, LLC works for both CVS Health and Best Buy.
Shared Lobbying Exposure
CVS Health
client
BGR GOVERNMENT AFFAIRS
lobbying firm
Alibaba Group Holding Limited
also a client
Kontoor Brands Inc
also a client
Samsung Electronics Co., Ltd.
also a client
+2 more
clients
MICHAEL BEST STRATEGIES LLC also lobbies for KKR & Co. Inc., Microsoft Corporation, T-Mobile
KOUNTOUPES DENHAM CARR & REID, LLC also lobbies for Best Buy Co Inc, T-Mobile
CONTINENTAL STRATEGY, LLC also lobbies for Samsung Electronics Co., Ltd.
THEGROUP DC, LLC also lobbies for Dell Technologies Inc
Why it matters: the same firm argues CVS Health’s case and its rivals’ — one hire buys a web of shared access that can’t be seen from outside. This network worsens CVS Health’s political-access score (see methodology for the exact factor).

Pumping Up Shareholder Value While the Pay Gap Widens

CVS Health’s CEO pay ratio is 503:1, the 3-year average of Compensation Actually Paid, relative to its median employee (SEC DEF 14A). The CEO’s three-year average package was about $31.8 million. The median CVS Health employee earned $63,262 that year — not enough to cover rent in most of the major metro areas where CVS operates its national pharmacy footprint.
Across fiscal years 2024 and 2025, CVS Health spent $3,023,000,000 on a deliberate reduction in shares outstanding that inflates per-share metrics and triggers executive performance bonuses, and paid out roughly $6,770,000,000 in dividends (SEC 10-K). Both flows of cash disproportionately enriched the wealthiest 10% of Americans, who own 93% of the stock market. No employee headcount is publicly disclosed for this period, so a precise per-worker raise equivalent cannot be computed — but the scale is plain: $3,023,000,000 in buybacks directed to shareholders, against a workforce whose median salary sits at $63,262 a year.
The data shows CVS Health didn’t have to choose between its investors and its workforce. It handed out roughly $6,770,000,000 in traditional dividends across 2024 and 2025 and still could have funded a meaningful worker raise on top of it. The company simply chose not to.
Buybacks also reduce the number of outstanding shares, which mechanically inflates Earnings Per Share (EPS) — a metric directly tied to executive performance bonuses. The same executives who approved $3,023,000,000 in buybacks benefit from the resulting EPS lift, while the CEO-to-median-worker pay gap sits at 503:1.
CVS Health paid an effective tax rate of 19.1% — 1.9 percentage points (pp) below the 21% federal statutory rate that Congress set, and 5.4pp below the 24.5% median paid by companies in the same sector. The company’s 10-K discloses that the single largest item cutting the tax bill was recognition of a basis difference in subsidiaries, which reduced the effective rate by 83.9pp — though a separate goodwill impairment charge added back 56.3pp, partially offsetting that reduction. The filing also discloses that Ireland’s statutory rate differential reduced CVS Health’s tax burden by 3.1pp. Total tax credits — covering research and development, energy, low-income housing, and other items — trimmed an additional 7.8pp from the effective rate, with energy-related credits alone accounting for 3.6pp. CVS Health chose to pay 1.9pp less than the rate Congress set and 5.4pp less than its own sector peers. That gap is not an accounting accident — it is a structural decision that shifts real tax burden off CVS Health’s balance sheet and onto everyone else. On top of that, CVS Health holds Unrecognized Tax Benefits equal to 15.0% of its pre-tax income — contested deductions it has claimed on its taxes that the Internal Revenue Service (IRS) has not yet agreed are valid.

Fines Treated as a Business Expense

CVS Health accumulated $357,762,787 in total fines across 35 cases between 2024-10-01 and 2026-09-30 (Good Jobs First) — the second-highest penalty total of any company in its sector. The source site carries the company’s full historical record; the figures here cover only the two-year tracking period from Q4 2024 through Q3 2026.
False Claims Act and related violations account for $254,592,280 of that total across just 6 cases, dwarfing every other offense category. Insurance violations were the most frequent type, with 17 separate cases over the two-year tracking period, totaling $5,003,510 — a pattern of recurring, lower-dollar insurance infractions sitting alongside a small number of very large False Claims Act settlements. This is not a story of isolated accidents; it is a recurring feature of how the company operates across its pharmacy, insurance, and healthcare subsidiaries.
INSURANCE VIOLATION
17 SEPARATE CASES
2024–2026 · $5 million in penalties
17 separate insurance violation penalties in 2024–2026 — CVS Health paid $5 million for the same category of offense, case after case.
The single largest fine was $117,700,000, levied in 2026 against CVS Health’s Aetna subsidiary by the Department of Justice (DOJ) Civil Division for a False Claims Act violation. The next-largest was a $45,000,000 consumer protection settlement with the Louisiana Attorney General in 2026, followed by a $37,760,000 False Claims Act settlement with the U.S. Attorney’s Office in 2025.
While regulators were fining CVS Health hundreds of millions of dollars, governments were simultaneously handing the company public money. CVS Health received $4,262,013 in public subsidies between 2024-10-01 and 2026-09-30 (Good Jobs First Subsidy Tracker), with the two largest awards — $2,144,657 in 2024 and $2,051,971 in 2025 — accounting for nearly all of the total.
Better Alternatives
DON'T JUST READ THE SCORE
Search any product in Shop to see how every retailer that carries it scores. Spend where it counts.
Shop with your values →
Political Access counts disclosed federal spending only. Dark money (501(c)(4) donations) is not included. How we score →
← Back to Retailer Search
N
ligarchy
Shop without feeding the Oligarchy.
© 2026 NOligarchy